Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Improved Survival in Peripheral T-Cell Lymphoma (PTCL) Following Complete Response to First-Line Chemotherapy: 10 Year Experience at the Royal Marsden and the Christie Hospitals 2002-2012

Blood (2015) 126 (23): 1499.

https://doi.org/10.1182/blood.V126.23.1499.1499

Published: 2015

Journal Articles

Limited Efficacy of Ponatinib in Myeloproliferative Neoplasms Associated with FGFR1 Fusion Genes

Sebastian Kreil, MD PhD, Lionel Adès, MD PhD, Martin Bommer, MD, Frank Stegelmann, MD, Mark E Ethell, MBBChir, MA, FRCP, FRCPath, Anna Lubking, MD, Peter Martin, MD, Ekkehard Eigendorff, MD, Wolf-Karsten Hofmann, MD, Nicholas C.P. Cross, PhD, Andreas Hochhaus, MD, Andreas Reiter, MD

Blood (2015) 126 (23): 2812.

https://doi.org/10.1182/blood.V126.23.2812.2812

Published: 2015

Journal Articles

The Natural History of Myeloma Patients Who Relapse Early After High Dose Therapy.

Nory Holle, Ping Wu, MBBS, MSc, Charlotte Pawlyn, MD, Radovan Saso, MD, MPhil, PhD, Jennifer G. Treleaven, MD, Michael Potter, MD PhD, Mark E Ethell, MD, Bronwen E. Shaw, MD PhD, Walter M Gregory, PhD, Sandra Croockewit, MD, Gareth J. Morgan, MD PhD, Faith E. Davies, MD

Blood (2012) 120 (21): 3125.

https://doi.org/10.1182/blood.V120.21.3125.3125

Published: 2012

Journal Articles

High Absolute T Regulatory Cell Counts and Resistance of CD8 Central Memory Cells to Killing by Fludarabine Predicts for Poor Responses to DLI in the Context of a Pre-DLI Lymphoreduction Strategy

Sameer Tulpule, MBBS, MD, MRCP, Nigel H. Russell, MD, Jenny Byrne, MD, PhD, Emma P Das-Gupta, MD, Mark E Ethell, Daniel Figueroa, J. Alejandro Madrigal, MD, PhD, Gareth J Morgan, MD PhD, Michael Potter, MA, MB, Phd, FRCP, (UK), FRCPath, Bronwen E. Shaw

Blood (2011) 118 (21): 1912.

https://doi.org/10.1182/blood.V118.21.1912.1912

Published: 2011

Journal Articles

High Readmission Rates Are Associated with a Significant Economic Burden and Poor Outcome in Patients with Grade 3/4 Acute GvHD

Fiona L Dignan, Michael N Potter, Mark E Ethell, Joy Brennan, Louise McNamara, Stephen O Evans, Claire E. Dearden, Faith E Davies, MD, Gareth J Morgan, MD PhD, Bronwen E. Shaw

Blood (2011) 118 (21): 2061.

https://doi.org/10.1182/blood.V118.21.2061.2061

Published: 2011

Journal Articles

The Presence of Minimal Residual Disease Pre- and Post-Transplant Is Predictive of Outcome in Recipients of Allogeneic Transplantation for Acute Myeloid Leukaemia.

Fiona L Dignan, Chloe Anthias, Mark E Ethell, Ricardo Morilla, Alison Morilla, Faith E Davies, MD, Gareth J Morgan, Michael N Potter, Bronwen E Shaw

Blood (2009) 114 (22): 2601.

https://doi.org/10.1182/blood.V114.22.2601.2601

Published: 2009

Journal Articles

A Single Institution’s Experience with Allogeneic Haematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukaemia: Analysis of Factors Leading to Improved Outcome

Pawel A Kaczmarek, Michael N Potter, Mark E Ethell, Jennifer G Treleaven, Faith E Davies, Claire E Dearden, Gareth J Morgan, Bronwen E Shaw

Blood (2008) 112 (11): 4322.

https://doi.org/10.1182/blood.V112.11.4322.4322

Published: 2008

Journal Articles

An Early CT-Diagnosis Based Treatment Strategy for Invasive Fungal Infection in Allogeneic Transplant Recipients Using Caspofungin First Line: An Effective Strategy with Low Mortality.

Fiona L Dignan, Stephen O Evans, Mark E Ethell, Bronwen E. Shaw, Unell BG Riley, Faith Davies, Jennifer G. Treleaven, Claire E. Dearden, Gareth J. Morgan, Michael N Potter

Blood (2008) 112 (11): 1149.

https://doi.org/10.1182/blood.V112.11.1149.1149

Published: 2008

Journal Articles

Alemtuzumab Administered by Subcutaneous Route Is Less Effective Than Intravenous Route for First Line Therapy of T-Cell Prolymphocytic Leukaemia: Results of a Pilot Study (UKCLL05)

Ami t S Khot, Estella Matutes, MD, PhD, Pawel A Kaczmarek, Mike Hamblin, Ashok Roy, Effie Grand, Mark E Ethell, Claire E Dearden, MD

Blood (2008) 112 (11): 4204.

https://doi.org/10.1182/blood.V112.11.4204.4204

Published: 2008

Journal Articles

Autologous Transplantation Is the Optimum Approach to the Management of Myeloma Patients with Extramedullary Disease at Presentation

Faith E. Davies, Ping Wu, Kevin Boyd, Radovan Saso, Michael N Potter, Mark E Ethell, Bronwen E Shaw, Jenny Treleaven, Sharon Dines, Gareth J Morgan

Blood (2008) 112 (11): 3313.

https://doi.org/10.1182/blood.V112.11.3313.3313

Published: 2008

Journal Articles

Prophylactic Defibrotide in Allogeneic Stem Cell Transplantation: Low Morbidity and Zero Mortality from Veno-Occlusive Disease.

Fiona L. Dignan, BSc, MRCP, Dorothy Gujral, MRCP, Mark E. Ethell, MD MRCP MRCPath, Jennifer Treleaven, FRCP FRCPath, Gareth Morgan, PhD FRCP FRCPath, Michael Potter, PhD FRCP FRCPath

Blood (2006) 108 (11): 2968.

https://doi.org/10.1182/blood.V108.11.2968.2968

Published: 2006

Journal Articles

Parainfluenza Virus Type 3 Post Stem Cell Transplant: High Prevalence but Low Mortality.

Fiona L. Dignan, BSc, MRCP, Caroline L. Alvares, BSc, MRCP, MRCPath, Unell Riley, MRCP, Mark E. Ethell, MD, MRCP, MRCPath, David C. Cunningham, MD, FRCP, Jennifer Treleavan, MD, FRCP, FRCPath, Michael Potter, PhD, FRCP, FRCPath

Blood (2005) 106 (11): 3229.

https://doi.org/10.1182/blood.V106.11.3229.3229

Published: 2005

NARROW

Improved Survival in Peripheral T-Cell Lymphoma (PTCL) Following Complete Response to First-Line Chemotherapy: 10 Year Experience at the Royal Marsden and the Christie Hospitals 2002-2012

Limited Efficacy of Ponatinib in Myeloproliferative Neoplasms Associated with FGFR1 Fusion Genes

The Natural History of Myeloma Patients Who Relapse Early After High Dose Therapy.

High Absolute T Regulatory Cell Counts and Resistance of CD8 Central Memory Cells to Killing by Fludarabine Predicts for Poor Responses to DLI in the Context of a Pre-DLI Lymphoreduction Strategy

High Readmission Rates Are Associated with a Significant Economic Burden and Poor Outcome in Patients with Grade 3/4 Acute GvHD

The Presence of Minimal Residual Disease Pre- and Post-Transplant Is Predictive of Outcome in Recipients of Allogeneic Transplantation for Acute Myeloid Leukaemia.

A Single Institution’s Experience with Allogeneic Haematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukaemia: Analysis of Factors Leading to Improved Outcome

An Early CT-Diagnosis Based Treatment Strategy for Invasive Fungal Infection in Allogeneic Transplant Recipients Using Caspofungin First Line: An Effective Strategy with Low Mortality.

Alemtuzumab Administered by Subcutaneous Route Is Less Effective Than Intravenous Route for First Line Therapy of T-Cell Prolymphocytic Leukaemia: Results of a Pilot Study (UKCLL05)

Autologous Transplantation Is the Optimum Approach to the Management of Myeloma Patients with Extramedullary Disease at Presentation

Prophylactic Defibrotide in Allogeneic Stem Cell Transplantation: Low Morbidity and Zero Mortality from Veno-Occlusive Disease.

Parainfluenza Virus Type 3 Post Stem Cell Transplant: High Prevalence but Low Mortality.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only